Annovis Bio ANVS
NYSE ANVS
$1.32 -0.06 (-4.71%)
As of: Sep 29, 2026 · 3:59 PM EDT

Annovis Bio (ANVS) Convertible Debt (2019)

Updated

Annovis Bio (ANVS) recorded Convertible Debt of $499,807 in Q4 2019.

Analysis

Annovis Bio (ANVS) Convertible Debt (2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Annovis Bio 58.80 Mn 58.80 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 499,807.00
API Access

Annovis Bio Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=ANVS&period=max&api_key=YOUR_API_KEY